<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27282159</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1926</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>56</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical pharmacokinetics</Title>
          <ISOAbbreviation>Clin Pharmacokinet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.</ArticleTitle>
        <Pagination>
          <StartPage>11</StartPage>
          <EndPage>24</EndPage>
          <MedlinePgn>11-24</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40262-016-0421-4</ELocationID>
        <Abstract>
          <AbstractText>Saxagliptin is an orally active, highly potent, selective and competitive dipeptidyl peptidase (DPP)-4 inhibitor used in the treatment of type 2 diabetes mellitus at doses of 2.5 or 5 mg once daily. DPP-4 is responsible for degrading the intestinally derived hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP-4 increases intact plasma GLP-1 and GIP concentrations, augmenting glucose-dependent insulin secretion. Both saxagliptin and its major active metabolite, 5-hydroxy saxagliptin, demonstrate high degrees of selectivity for DPP-4 compared with other DPP enzymes. Saxagliptin is orally absorbed and can be administered with or without food. The half-life of plasma DPP-4 inhibition with saxagliptin 5 mg is ~27 h, which supports a once-daily dosing regimen. Saxagliptin is metabolized by cytochrome P450 (CYP) 3A4/5 and is eliminated by a combination of renal and hepatic clearance. No clinically meaningful differences in saxagliptin or 5-hydroxy saxagliptin pharmacokinetics have been detected in patients with hepatic impairment. No clinically meaningful differences in saxagliptin or 5-hydroxy saxagliptin pharmacokinetics have been detected in patients with mild renal impairment, whereas dose reduction is recommended in patients with moderate or severe renal impairment because of greater systemic exposure [the area under the plasma concentration-time curve (AUC)] to saxagliptin total active moieties. Clinically relevant drug-drug interactions have not been detected; however, limiting the dose to 2.5 mg once daily is recommended in the USA when saxagliptin is coadministered with strong CYP inhibitors, because of increased saxagliptin exposure. In summary, saxagliptin has a predictable pharmacokinetic and pharmacodynamic profile.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Boulton</LastName>
            <ForeName>David W</ForeName>
            <Initials>DW</Initials>
            <AffiliationInfo>
              <Affiliation>Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. david.boulton2@astrazeneca.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Clin Pharmacokinet</MedlineTA>
        <NlmUniqueID>7606849</NlmUniqueID>
        <ISSNLinking>0312-5963</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>89750-14-1</RegistryNumber>
          <NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.1</RegistryNumber>
          <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>8</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27282159</ArticleId>
        <ArticleId IdType="doi">10.1007/s40262-016-0421-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s40262-016-0421-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Clin Pharmacokinet. 2015 Jan;54(1):1-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25331711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2012 Aug;14(8):762-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22471248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BMC Pharmacol. 2012 Apr 04;12:2</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22475049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2009 Sep;32(9):1649-55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19478198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 2013 Mar;75(3):763-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22823746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2012 Aug 1;51(8):501-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22686547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Metab Dispos. 2009 Jun;37(6):1164-71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19251818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Med Res Opin. 2011 Apr;27(4):863-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21323504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharm Res. 1995 Mar;12(3):413-20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7617530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 2010 Oct;50(10):1211-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20150522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2012 Sep;14(9):810-20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22486990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2011 Jul;13(7):604-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21332626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2010 Sep;49(9):573-88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20690781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 2011 Apr;50(4):253-65</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21348538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Endocrinol Metab. 2009 Dec;94(12):4810-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19864452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2015 Mar;38(3):376-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25352655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Core Evid. 2010 Oct 21;5:23-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21042540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol. 2011;3:13-25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22287853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Med Chem. 2005 Jul 28;48(15):5025-37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16033281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 2009 Feb;85(2):173-81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2011 Sep;13(9):850-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21554520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Interv Aging. 2013;8:419-30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23626461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2012 Dec;14(12):1155-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22776778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancet. 2006 Nov 11;368(9548):1696-705</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17098089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabet Med. 2013 Dec;30(12):1472-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23802840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2009 Jun;11(6):611-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19515181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Expert Opin Drug Metab Toxicol. 2016;12 (4):467-73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26878666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2014 May;16(5):443-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24205943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curr Med Res Opin. 2009 Oct;25(10):2401-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19650754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 2011 Jul;72(1):92-102</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21651615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 15;889-890:77-86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22349123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2015 Jul;17(7):630-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25761977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2015 Oct;75(15):1783-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26403305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Interv Aging. 2014 Sep 04;9:1479-87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25214775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drug Metab Dispos. 2012 Jul;40(7):1345-56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22496391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetol Metab Syndr. 2012 Jul 24;4(1):36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22828124</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
